查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1941887

癌症疫苗市场规模、份额和趋势分析报告：按疫苗类型、适应症类型、技术类型、地区和细分市场预测（2026-2033 年）

Cancer Vaccine Market Size, Share & Trends Analysis Report By Vaccine Type (Preventive Cancer Vaccine, Therapeutic Cancer Vaccine), By Indication Type, By Technology Type, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

癌症疫苗市场概况

2025年全球癌症疫苗市场规模估计为99.3亿美元，预计2033年将达到233.1亿美元。

预计从 2026 年到 2033 年，该市场将以 11.30% 的复合年增长率成长。这一增长主要受全球癌症负担加重、免疫治疗方法的广泛应用以及疫苗技术（如 mRNA、树突细胞平台和个人化新抗原疫苗）的快速发展所驱动。

由于全球癌症负担日益加重，以及人们对免疫疗法作为长期治疗方案的兴趣日益浓厚，癌症疫苗产业正在迅速扩张。 mRNA和DNA平台等疫苗技术的进步，显着提高了疫苗设计能力，使疫苗能够比传统治疗方法更有效地诱导免疫系统识别特异性抗原并摧毁癌细胞。

人们对癌症疫苗的兴趣日益浓厚，尤其是在治疗选择有限的固体癌领域。这主要得益于製药公司和学术研究机构加大投入，寻求能够减少副作用并改善患者预后的个人化疗法。例如，2026年1月有报告指出，Moderna和默克联合研发的个人化癌症疫苗与Keytruda合併使用，在长期追踪中，高风险黑色素瘤患者的復发或死亡风险显着降低。这项发现增强了人们对疫苗疗法的信心，并推动了进一步的临床研发和资金筹措。

癌症疫苗产业的另一个成长要素是科学技术创新的快速发展，这些创新提高了候选疫苗的准确性和有效性。抗原辨识、新型抗原标标靶化和计算生物学等新技术，使得针对个别肿瘤独特基因谱客製化疫苗的研发成为可能，这对于激发强效的免疫反应至关重要。不断扩展的临床试验计画表明，研究人员和投资者对癌症疫苗在多种癌症类型（包括传统上难以治疗的癌症）中取得显着疗效的潜力越来越有信心。

例如，2025年7月，佛罗里达大学的研究人员开发出一种实验性mRNA疫苗，该疫苗在临床前模型中诱发了针对肿瘤的强效抗癌免疫反应。这项成果凸显了下一代疫苗的潜力以及支撑市场成长的技术发展势头。

市场成长也得益于有利的政策环境、意识提升，以及新型诊断工具与疫苗策略的结合。各国政府和卫生组织正在加大对免疫疗法研究的投入，生技公司与研究机构的合作也日益增加。这些因素正在加速产品开发和监管核准流程。

此外，新冠疫情期间疫苗平台的成功应用增强了人们对mRNA技术在其他疾病（包括癌症）治疗方面的信心，从而推动了投资成长，并加速了研究成果向临床应用的转化。例如，俄罗斯于2025年9月宣布，其采用先进mRNA技术研发的新型癌症疫苗Enteromix将在获得监管部门核准后投入临床使用，并免费提供给患者。这正是技术进步和政策支持共同推动市场扩张的例子。

目录

第一章：调查方法和范围

第二章执行摘要

第三章：癌症疫苗市场的变数、趋势和范围

  • 市场谱系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章：癌症疫苗市场：按疫苗类型分類的业务分析

  • 按疫苗类型分類的市场份额（2025 年和 2033 年）
  • 按疫苗类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 预防性癌症疫苗
  • 用于治疗的癌症疫苗
  • 其他的

第五章：癌症疫苗市场：按适应症类型分類的业务分析

  • 按适应症类型分類的市场份额（2025 年和 2033 年）
  • 按适应症类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 摄护腺癌
  • 膀胱癌
  • 恶性黑色素瘤
  • 子宫颈癌
  • 其他的

第六章：癌症疫苗市场：按技术类型分類的业务分析

  • 按技术类型分類的市场份额（2025 年和 2033 年）
  • 按技术类型分類的市场规模、预测与趋势分析（2021年至2033年）
  • 重组癌症疫苗
  • 全细胞癌症疫苗
  • 病毒载体和DNA癌症疫苗
  • 其他技术

第七章：癌症疫苗市场：区域估算与趋势分析

  • 区域市场占有率分析（2025 年和 2033 年）
  • 区域市场概览
  • 2021年至2033年市场规模及预测趋势分析：
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Merck &Co., Inc.
    • GSK plc
    • Dendreon Pharmaceuticals LLC.
    • Dynavax Technologies.
    • Ferring BV
    • Amgen, Inc.
    • Moderna, Inc.
    • Sanofi
    • AstraZeneca
    • Bristol-Myers Squibb Company
Product Code: GVR-4-68040-096-2

Cancer Vaccine Market Summary

The global cancer vaccine market size was estimated at USD 9.93 billion in 2025 and is projected to reach USD 23.31 billion by 2033, growing at a CAGR of 11.30% from 2026 to 2033. This growth is primarily driven by the rising global burden of cancer, increasing adoption of immunotherapy-based treatments, and rapid advancements in vaccine technologies such as mRNA, dendritic cell platforms, and personalized neoantigen vaccines.

The Cancer Vaccine industry is expanding rapidly because of the rising global burden of cancer and the increasing emphasis on immunotherapy as a viable long-term treatment option. Advances in vaccine technology, such as mRNA and DNA platforms, have significantly improved the ability to design vaccines that teach the immune system to recognize cancer-specific antigens and destroy tumor cells more effectively than traditional therapies.

Interest in Cancer Vaccine has been bolstered by growing investment from pharmaceutical companies and academic research groups seeking more personalized treatments that can reduce side effects and improve patient outcomes, especially in solid tumors where options remain limited. For instance, in January 2026, Moderna and Merck reported that their personalized cancer vaccine used with Keytruda showed a sustained reduction in risk of recurrence or death in high-risk melanoma patients during long-term follow-up, reinforcing confidence in vaccine approaches and driving further clinical development and funding.

Another major growth factor in the Cancer Vaccine industry is the rapid pace of scientific innovation improving the precision and effectiveness of vaccine candidates. New techniques in antigen identification, neoantigen targeting, and computational biology have enabled vaccines to be tailored to the unique genetic profile of individual tumors, which is critical for triggering a robust immune response. The expanding pipeline of clinical trials demonstrates increasing confidence among researchers and investors that Cancer Vaccine can deliver meaningful benefits across multiple cancer types, including those historically difficult to treat.

For instance, in July 2025, Scientists at the University of Florida developed an experimental mRNA vaccine that triggered a strong anticancer immune response against tumors in preclinical models, highlighting both the promise of next-generation vaccines and the technological momentum supporting market growth.

Market growth is also propelled by supportive policy environments, increasing public awareness of cancer prevention and early detection, and the integration of novel diagnostic tools that work in tandem with vaccine strategies. Governments and health agencies have intensified funding for immunotherapy research, and collaborations between biotech firms and research institutions are becoming more common, which accelerates product development and regulatory approval pathways.

Moreover, the success of vaccine platforms during the COVID-19 pandemic has reinforced confidence in mRNA technology for other diseases, including cancer, leading to greater investment and quicker translation of research into clinical applications. For instance, in September 2025, Russia announced that its new cancer vaccine Enteromix, developed using advanced mRNA technology, was ready for clinical use and would be provided free to patients following regulatory approval, illustrating both the technological progress and policy support driving market expansion.

Global Cancer Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Cancer Vaccine market report based on vaccine type, indication type, technology type, and region:

  • Vaccine Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Preventive Cancer Vaccine
  • Therapeutic Cancer Vaccine
  • Others
  • Indication Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Prostate Cancer
  • Bladder Cancer
  • Melanoma
  • Cervical Cancer
  • Other
  • Technology Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Recombinant Cancer Vaccine
  • Whole-cell Cancer Vaccine
  • Viral Vector and DNA Cancer Vaccine
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Vaccine Type
    • 1.2.2. Indication Type
    • 1.2.3. Technology Type
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Cancer Vaccine Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Cancer Vaccine Market: Vaccine Type Business Analysis

  • 4.1. Vaccine Type Market Share, 2025 & 2033
  • 4.2. Vaccine Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Vaccine Type, 2021 to 2033 (USD Million)
  • 4.4. Preventive Cancer Vaccine
    • 4.4.1. Preventive Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 4.5. Therapeutic Cancer Vaccine
    • 4.5.1. Therapeutic Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Cancer Vaccine Market: Indication Type Business Analysis

  • 5.1. Indication Type Market Share, 2025 & 2033
  • 5.2. Indication Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication Type, 2021 to 2033 (USD Million)
  • 5.4. Prostate Cancer
    • 5.4.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
  • 5.5. Bladder Cancer
    • 5.5.1. Bladder Cancer Market, 2021 - 2033 (USD Million)
  • 5.6. Melanoma
    • 5.6.1. Melanoma Market, 2021 - 2033 (USD Million)
  • 5.7. Cervical Cancer
    • 5.7.1. Cervical Cancer Market, 2021 - 2033 (USD Million)
  • 5.8. Other
    • 5.8.1. Other Market, 2021 - 2033 (USD Million)

Chapter 6. Cancer Vaccine Market: Technology Type Business Analysis

  • 6.1. Technology Type Market Share, 2025 & 2033
  • 6.2. Technology Type Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by technology type, 2021 to 2033 (USD Million)
  • 6.4. Recombinant Cancer Vaccine
    • 6.4.1. Recombinant Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 6.5. Whole-cell Cancer Vaccine
    • 6.5.1. Whole-cell Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 6.6. Viral Vector and DNA Cancer Vaccine
    • 6.6.1. Viral Vector and DNA Cancer Vaccine Market, 2021 - 2033 (USD Million)
  • 6.7. Other Technologies
    • 6.7.1. Other Technologies Market, 2021 - 2033 (USD Million)

Chapter 7. Cancer Vaccine Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2025 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Cancer Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Technology Type Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Technology Type Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Technology Type Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Technology Type Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Technology Type Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Technology Type Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Technology Type Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Technology Type Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Technology Type Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Technology Type Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Technology Type Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Technology Type Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Technology Type Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Technology Type Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Technology Type Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Technology Type Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Technology Type Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Technology Type Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Technology Type Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Technology Type Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Technology Type Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Technology Type Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Technology Type Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Cancer Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. GSK plc
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Dendreon Pharmaceuticals LLC.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Dynavax Technologies.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Ferring B.V.
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Amgen, Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Moderna, Inc.
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Sanofi
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. AstraZeneca
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Bristol-Myers Squibb Company
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Cancer Vaccine market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 5 Global Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 6 Global Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 7 North America Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 9 North America Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 10 North America Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 11 U.S. Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 13 U.S. Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 14 Canada Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 15 Canada Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 16 Canada Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 17 Mexico Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 19 Mexico Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 20 Europe Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 22 Europe Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 23 Europe Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 24 UK Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 25 UK Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 26 UK Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 27 Germany Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 28 Germany Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 29 Germany Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 30 France Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 31 France Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 32 France Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 33 Italy Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 34 Italy Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 35 Italy Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 36 Spain Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 37 Spain Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 38 Spain Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 39 Norway Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 40 Norway Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 41 Norway Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 42 Denmark Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 43 Denmark Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 44 Denmark Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 45 Sweden Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 46 Sweden Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 47 Sweden Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Cancer Vaccine market, by indication type, 2021 - 2033 (USD
  • Table 51 Asia Pacific Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 52 Japan Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 53 Japan Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 54 Japan Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 55 China Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 56 China Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 57 China Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 58 India Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 59 India Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 60 India Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 61 Australia Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 62 Australia Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 63 Australia Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 64 South Korea Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 65 South Korea Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 66 South Korea Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 67 Thailand Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 68 Thailand Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 69 Thailand Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 70 Latin America Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 73 Latin America Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 74 Brazil Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 76 Brazil Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 77 Argentina Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 79 Argentina Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Cancer Vaccine market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 84 South Africa Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 86 South Africa Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 90 UAE Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 91 UAE Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 92 UAE Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Cancer Vaccine market, by vaccine type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Cancer Vaccine market, by indication type, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Cancer Vaccine market, by technology type, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Cancer Vaccine market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Competitive landscape
  • Fig. 10 Cancer Vaccine market dynamics
  • Fig. 11 Cancer Vaccine market: Porter's five forces analysis
  • Fig. 12 Cancer Vaccine market: PESTLE analysis
  • Fig. 13 Vaccine Type market, 2021 - 2033 (USD Million)
  • Fig. 14 Preventive Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 15 Therapeutic Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 16 Others market, 2021 - 2033 (USD Million)
  • Fig. 17 Indication Type market, 2021 - 2033 (USD Million)
  • Fig. 18 Prostate Cancer market, 2021 - 2033 (USD Million)
  • Fig. 19 Bladder Cancer market, 2021 - 2033 (USD Million)
  • Fig. 20 Melanoma market, 2021 - 2033 (USD Million)
  • Fig. 21 Cervical Cancer market, 2021 - 2033 (USD Million)
  • Fig. 22 Other market, 2021 - 2033 (USD Million)
  • Fig. 23 Technology Type market, 2021 - 2033 (USD Million)
  • Fig. 24 Recombinant Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 25 Whole-cell Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 26 Viral Vector and DNA Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 27 Other Technologies market, 2021 - 2033 (USD Million)
  • Fig. 28 Cancer Vaccine market revenue, by region
  • Fig. 29 Regional marketplace: Key takeaways
  • Fig. 30 North America Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. country dynamics
  • Fig. 32 U.S. Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada country dynamics
  • Fig. 34 Canada Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico country dynamics
  • Fig. 36 Mexico Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 37 Europe Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 38 UK country dynamics
  • Fig. 39 UK Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 40 Germany country dynamics
  • Fig. 41 Germany Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 42 France country dynamics
  • Fig. 43 France Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 44 Italy country dynamics
  • Fig. 45 Italy Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 46 Spain country dynamics
  • Fig. 47 Spain Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 48 Norway country dynamics
  • Fig. 49 Norway Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 50 Sweden country dynamics
  • Fig. 51 Sweden Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 54 Asia Pacific Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 55 Japan country dynamics
  • Fig. 56 Japan Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 57 China country dynamics
  • Fig. 58 China Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 59 India country dynamics
  • Fig. 60 India Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 61 Australia country dynamics
  • Fig. 62 Australia Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 65 Thailand country dynamics
  • Fig. 66 Thailand Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 67 Latin America Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 68 Brazil country dynamics
  • Fig. 69 Brazil Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 70 Argentina country dynamics
  • Fig. 71 Argentina Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 72 MEA Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 73 South Africa country dynamics
  • Fig. 74 South Africa Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 75 Saudi Arabia country dynamics
  • Fig. 76 Saudi Arabia Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 77 UAE country dynamics
  • Fig. 78 UAE Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 79 Kuwait country dynamics
  • Fig. 80 Kuwait Cancer Vaccine market, 2021 - 2033 (USD Million)
  • Fig. 81 Company categorization
  • Fig. 82 Company market position analysis
  • Fig. 83 Strategic framework